Form 4: Omada Health Insider Sells Shares Under 10b5-1 Plan

Omada Health President Wei-Li Shao sold 2,829 shares of common stock for approximately $36,000 under a pre-arranged 10b5-1 trading plan.

Summary

• Wei-Li Shao, President of Omada Health, Inc., reported a transaction involving the sale of 2,829 shares of common stock.
• The sale occurred on April 8, 2026, with a weighted average price of $12.7062 per share.
• The total value of the transaction was approximately $36,000.
• This transaction was executed as part of a Rule 10b5-1 trading plan adopted by Mr. Shao on August 15, 2025.
• Following the transaction, Mr. Shao beneficially owns 328,850 shares of Omada Health common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be a negative signal, the use of a 10b5-1 plan mitigates concerns about opportunistic trading, and the executive retains a substantial stake.

Positives

• The sale was conducted under a pre-established 10b5-1 trading plan, indicating a planned and orderly divestiture rather than a reaction to negative news.
• The reporting person continues to hold a significant number of shares (328,850) after the sale, suggesting ongoing confidence in the company.

Negatives

• An insider, the President of the company, has sold a portion of their holdings.
• The sale represents a reduction in direct beneficial ownership by a key executive.

Risks

• Insider selling can sometimes be interpreted by the market as a signal of reduced confidence, potentially impacting share price negatively.
• The specific reasons for the sale under the 10b5-1 plan are not detailed, leaving room for speculation.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing. The filing solely reports a past transaction.

Management Comments

• The transaction was made pursuant to a 10b5-1 trading plan adopted by Wei-Li Shao on August 15, 2025.
• The transaction was executed in multiple trades at prices ranging from $12.51 to $13.05. The price reported reflects the weighted average price.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event in the healthcare technology sector. Such plans are designed to allow executives to sell shares without being accused of insider trading, but they can still influence market perception.

Stakeholder Impact

• Shareholders: May view the sale with caution, although the 10b5-1 plan provides a degree of reassurance. The continued large holding by the executive may temper negative sentiment.
• Employees: May interpret the sale as a sign of executive confidence or a need for personal liquidity, depending on broader company performance.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific insider transaction.

Next Steps

• The reporting person may continue to execute trades under the existing 10b5-1 plan.
• The SEC staff, issuer, or a security holder may request further information regarding the transaction details.

Key Dates

Recommendation

The sale is executed under a pre-defined 10b5-1 plan, which is a standard practice for insiders. The executive retains a significant number of shares, suggesting continued commitment. Without further negative news or financial performance indicators, this transaction alone does not warrant a strong buy or sell recommendation.

Keywords

Omada Health, OMDA, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership, Executive Sale, Common Stock